JP2009536155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536155A5 JP2009536155A5 JP2009505472A JP2009505472A JP2009536155A5 JP 2009536155 A5 JP2009536155 A5 JP 2009536155A5 JP 2009505472 A JP2009505472 A JP 2009505472A JP 2009505472 A JP2009505472 A JP 2009505472A JP 2009536155 A5 JP2009536155 A5 JP 2009536155A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- optionally substituted
- compound according
- independently
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 49
- 201000011510 cancer Diseases 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- -1 C 3-6 cycloaliphatic Chemical group 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010017758 Gastric cancer Diseases 0.000 claims description 2
- 206010024324 Leukaemias Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025650 Malignant melanoma Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000011278 mitosis Effects 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims 30
- 125000005843 halogen group Chemical group 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- 102000001253 Protein Kinases Human genes 0.000 claims 4
- 108060006633 Protein Kinases Proteins 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 4
- 125000005842 heteroatoms Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004429 atoms Chemical group 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 210000003169 Central Nervous System Anatomy 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 206010061590 Blood disease Diseases 0.000 claims 1
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010052739 Immunodeficiency disorder Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 1
- 108010008267 Nerve Growth Factors Proteins 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 102100019436 PLK1 Human genes 0.000 claims 1
- 101700062434 PLK1 Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000001028 anti-proliferant Effects 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 201000002393 blood protein disease Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000000973 chemotherapeutic Effects 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 201000002138 hematopoietic system disease Diseases 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 201000009673 liver disease Diseases 0.000 claims 1
- 230000001404 mediated Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 claims 1
- 230000002062 proliferating Effects 0.000 claims 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 108010056274 polo-like kinase 1 Proteins 0.000 description 10
- 210000004027 cells Anatomy 0.000 description 6
- 0 CC[C@@](C)C(*N)N(C1C(NC2*CCC2)=NC(NC(C#CC2)=C(C)*=C2C(N(C)C)=O)=N[C@]1C)C#C Chemical compound CC[C@@](C)C(*N)N(C1C(NC2*CCC2)=NC(NC(C#CC2)=C(C)*=C2C(N(C)C)=O)=N[C@]1C)C#C 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 201000009030 carcinoma Diseases 0.000 description 3
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 2
- 108020004459 Small Interfering RNA Proteins 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002924 silencing RNA Substances 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 210000004881 tumor cells Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 102100007788 APC Human genes 0.000 description 1
- 101700010938 APC Proteins 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 108010000750 BRCA2 Protein Proteins 0.000 description 1
- 102000002280 BRCA2 Protein Human genes 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 102100012419 CDC25C Human genes 0.000 description 1
- 101710012460 CDC25C Proteins 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 208000005017 Glioblastoma Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- 208000003849 Large Cell Carcinoma Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 206010038038 Rectal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000649 Small Cell Carcinoma Diseases 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 102100019730 TP53 Human genes 0.000 description 1
- 101710026335 TP53 Proteins 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000023359 cell cycle switching, meiotic to mitotic cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000467 effect on cytodieresis Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000005160 follicular thyroid carcinoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000000394 mitotic Effects 0.000 description 1
- 201000008006 pharynx cancer Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 201000010208 seminoma Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 230000020347 spindle assembly Effects 0.000 description 1
- 230000019130 spindle checkpoint Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79132706P | 2006-04-12 | 2006-04-12 | |
US60/791,327 | 2006-04-12 | ||
US83872006P | 2006-08-18 | 2006-08-18 | |
US60/838,720 | 2006-08-18 | ||
PCT/US2007/009006 WO2007120752A2 (en) | 2006-04-12 | 2007-04-12 | 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009536155A JP2009536155A (ja) | 2009-10-08 |
JP2009536155A5 true JP2009536155A5 (zh) | 2010-05-27 |
JP5313875B2 JP5313875B2 (ja) | 2013-10-09 |
Family
ID=38544378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009505472A Expired - Fee Related JP5313875B2 (ja) | 2006-04-12 | 2007-04-12 | 増殖性疾患の処置のためのタンパク質キナーゼplk1の阻害剤として有用な4,5−ジヒドロ−[1,2,4]トリアゾロ[4,3−f]プテリジン |
Country Status (17)
Country | Link |
---|---|
US (3) | US7763629B2 (zh) |
EP (1) | EP2010542B1 (zh) |
JP (1) | JP5313875B2 (zh) |
KR (1) | KR101432316B1 (zh) |
AR (1) | AR060432A1 (zh) |
AT (1) | ATE542823T1 (zh) |
AU (1) | AU2007238690B2 (zh) |
CA (1) | CA2649324A1 (zh) |
ES (1) | ES2381212T3 (zh) |
HK (1) | HK1134486A1 (zh) |
IL (1) | IL194699A (zh) |
MX (1) | MX2008013110A (zh) |
NO (1) | NO20084747L (zh) |
NZ (1) | NZ571969A (zh) |
RU (1) | RU2441006C2 (zh) |
TW (1) | TW200808805A (zh) |
WO (1) | WO2007120752A2 (zh) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ583061A (en) * | 2007-08-15 | 2012-06-29 | Vertex Pharma | 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases |
MX2010006457A (es) | 2007-12-19 | 2010-07-05 | Amgen Inc | Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular. |
ATE531372T1 (de) | 2008-04-07 | 2011-11-15 | Amgen Inc | Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren |
CA2728830A1 (en) * | 2008-06-23 | 2010-01-21 | Jean-Damien Charrier | Protein kinase inhibitors |
WO2010008454A1 (en) * | 2008-06-23 | 2010-01-21 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors |
CN102548994A (zh) | 2009-09-25 | 2012-07-04 | 沃泰克斯药物股份有限公司 | 用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法 |
RU2012116526A (ru) * | 2009-09-25 | 2013-10-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы |
US8541418B2 (en) | 2009-12-23 | 2013-09-24 | Elan Pharmaceutical, Inc. | Inhibitors of polo-like kinase |
EP2535059A4 (en) * | 2010-02-10 | 2014-03-12 | Public Univ Corp Yokohama City | USE OF A MSIN3B-BINDING COMPOUND WHICH BINDES SPECIFICLY TO THE SILENCER FACTOR OF NRSF NEURONIC SPECIFICATION |
ES2706066T3 (es) | 2010-07-02 | 2019-03-27 | Univ Health Network | Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas |
BR112013008526A2 (pt) | 2010-10-08 | 2016-07-12 | Elan Pharm Inc | inibidores de quinase do tipo polo |
US8569331B2 (en) | 2010-11-01 | 2013-10-29 | Arqule, Inc. | Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds |
EP2688887B1 (en) | 2011-03-23 | 2015-05-13 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
MD4300C1 (ro) * | 2012-12-28 | 2015-03-31 | Государственный Университет Молд0 | Inhibitor al proliferării celulelor HepG2 în cancerul hepatic în bază de cloro-[2-fenil(piridin-2-il)metanon-4-(3-metoxifenil)tiosemicarbazono]nichel |
WO2016183071A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Hetero-tricyclic compounds and their use for the treatment of cancer |
WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
US10053465B2 (en) | 2015-08-26 | 2018-08-21 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
SI3436461T1 (sl) | 2016-03-28 | 2024-03-29 | Incyte Corporation | Pirolotriazinske spojine kot tam-inhibitorji |
RS62872B1 (sr) | 2017-09-27 | 2022-02-28 | Incyte Corp | Soli derivata pirrolotriazina korisne kao tam inhibitori |
CN117771250A (zh) | 2018-06-29 | 2024-03-29 | 因赛特公司 | Axl/mer抑制剂的制剂 |
CN109734809A (zh) * | 2019-02-27 | 2019-05-10 | 南方科技大学 | 治疗性的人Plk1蛋白单克隆抗体及其制备方法 |
JP2023540728A (ja) * | 2021-08-10 | 2023-09-26 | オップテラ インコーポレイテッド | 新規plk1分解誘導化合物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA973884B (en) | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
CA2500727A1 (en) * | 2002-10-03 | 2004-04-15 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
BRPI0411347A (pt) | 2003-06-10 | 2006-07-11 | Pfizer | combinações terapêuticas compreendendo inibidores de pde e antagonistas dos receptores de vasopressina para o tratamanento de dismenorréia |
GB0315966D0 (en) * | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
GB0400700D0 (en) | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
GB0412874D0 (en) | 2004-06-09 | 2004-07-14 | Pfizer Ltd | Novel pharmaceuticals |
DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
-
2007
- 2007-04-12 KR KR1020087027593A patent/KR101432316B1/ko not_active IP Right Cessation
- 2007-04-12 AT AT07755318T patent/ATE542823T1/de active
- 2007-04-12 WO PCT/US2007/009006 patent/WO2007120752A2/en active Application Filing
- 2007-04-12 JP JP2009505472A patent/JP5313875B2/ja not_active Expired - Fee Related
- 2007-04-12 MX MX2008013110A patent/MX2008013110A/es active IP Right Grant
- 2007-04-12 ES ES07755318T patent/ES2381212T3/es active Active
- 2007-04-12 AR ARP070101560A patent/AR060432A1/es unknown
- 2007-04-12 AU AU2007238690A patent/AU2007238690B2/en not_active Ceased
- 2007-04-12 RU RU2008144584/04A patent/RU2441006C2/ru not_active IP Right Cessation
- 2007-04-12 NZ NZ571969A patent/NZ571969A/en not_active IP Right Cessation
- 2007-04-12 TW TW096112918A patent/TW200808805A/zh unknown
- 2007-04-12 US US11/786,578 patent/US7763629B2/en not_active Expired - Fee Related
- 2007-04-12 CA CA002649324A patent/CA2649324A1/en not_active Abandoned
- 2007-04-12 EP EP07755318A patent/EP2010542B1/en not_active Not-in-force
-
2008
- 2008-10-12 IL IL194699A patent/IL194699A/en not_active IP Right Cessation
- 2008-11-10 NO NO20084747A patent/NO20084747L/no not_active Application Discontinuation
-
2010
- 2010-01-08 HK HK10100194.2A patent/HK1134486A1/zh not_active IP Right Cessation
- 2010-06-08 US US12/796,174 patent/US8067417B2/en not_active Expired - Fee Related
-
2011
- 2011-10-05 US US13/253,196 patent/US8524902B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009536155A5 (zh) | ||
CN110305109B (zh) | 新型取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途 | |
JP2009533452A5 (zh) | ||
CN106536480B (zh) | 吡咯烷-2,5-二酮衍生物、药物组合物及用作ido1抑制剂的方法 | |
TWI556820B (zh) | Hsp90抑制劑之組合 | |
US8642602B2 (en) | Method of inhibiting fibrogenesis and treating fibrotic disease | |
ES2400070T3 (es) | Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos | |
JP2021536458A (ja) | アリール炭化水素レセプター・アンタゴニスト及び使用方法 | |
TW201823232A (zh) | 含有取代的吡啶酮之三環化合物及其使用方法 | |
RU2008144584A (ru) | 4,5-дигидро-[1,2,4]триазоло[4,3-f]птеридины в качестве ингибиторов протеинкиназы plk1 для лечения пролиферативных заболеваний | |
JP2009541223A5 (zh) | ||
JP2017513942A (ja) | Mertk特異的ピロロピリミジン化合物 | |
JP2010513285A5 (zh) | ||
JP2011521968A5 (zh) | ||
JP2017523991A (ja) | グルタミナーゼ阻害剤の結晶形態 | |
JP2010535211A (ja) | 炎症性障害、脱髄障害および癌を治療するためのインダゾール化合物 | |
TW201107331A (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
US11013830B2 (en) | 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential | |
WO2014036242A2 (en) | Benzothiazole or benzoxazole compounds as sumo activators | |
JP2013501808A (ja) | アポトーシスを促進し、かつ転移を阻害する方法 | |
AU2014280354A1 (en) | Combinations for the treatment of cancer comprising a Mps-1 kinase inhibitor and a mitotic inhibitor | |
US20130324520A1 (en) | Rxrg modulators for the treatment of cancer | |
CN105658634B (zh) | 作为TCR-Nck相互作用的抑制剂的被醇盐取代的色烯衍生物 | |
TW202327611A (zh) | 使用btk抑制劑和p13激酶抑制劑的組合治療癌症之方法 | |
CN112574176B (zh) | 一种杂芳基类化合物及其应用 |